Rpg Life Sciences Limited · NSE:RPGLIFE
Rpg Life Sciences — Q1 FY26 Earnings Presentation
28 slides from Rpg Life Sciences's earnings presentation, Jul 25, 2025
Slide 1: Exchange filing cover letter
July 25, 2025 To, The Manager BSE Limited Listing Department Corporate Relationship Department National Stock Exchange of India Limited Floor 25, P.J. Towers Exchange Plaza, 5th Floor Dalal Street Plot No. C1, ‘G’ Block, Bandra-Kurla Complex Mumbai 400 001. Bandra (East), Mumbai 400 051. Symbol: RPG
Slide 2: Investors' Presentation Q1 FY26
Investors’ Presentation Q1 FY26
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward‐looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: RPG Group: Powered by Passion, Driven by Ethics
RPG Group: Powered by Passion, Driven by Ethics RPG Enterprises was founded in 1979. The group currently operates various businesses in Infrastructure, Technology, Life Sciences, Plantations and Tyre industries. The group has business history dating back to 1820 AD in banking, textiles, jute and tea
Slide 5: RPG Life Sciences: An Integrated Pharmaceutical Company
RPG Life Sciences: An Integrated Pharmaceutical Company RPG Life Sciences is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. Domestic Formulations (DF) Leader in Immunosuppr
Slide 6: RPG Life Sciences: Product Portfolio
RPG Life Sciences: Product Portfolio Strong ‘Textbook’ brands ; ↑ Chronic and Specialty therapies Key Therapies DF Key Products Legacy Portfolio New Portfolio Nephrology Specialty Chronic Immunosuppressants Textbook Brands Life Cycle Management (Existing Products) Rheumatology Trastuzumab Azathiopri
Slide 7: Business Operations
Business Operations LZ An @> FPG Company = ———————————— RPG LIFE SCIENCES
Slide 8: Building a Strong-Consistent-Profitable Business
Building a Strong‐Consistent‐Profitable Business 1 2 3 4 Business Focusing Building Energizing Transformation on Execution Competitiveness Happy Teams 6 >10 3‐4x 88% Bold Moves High Impact Projects Share of voice Happiness Score
Slide 9: Business Transformation
1 Business Transformation Bold Move 1 Galvanizing Organization to an “Inspiring Purpose”: Framing and embedding in the organisation Bold Move 2 “Small Brands” to Building “Mega Brand of 100 cr +; future 500 cr OTC”: Naprosyn Bold Move 3 “Small Product” to Building “Mega Rx Portfolio of 100 cr +; Pot
Slide 10: Focusing on Execution
2 Focusing on Execution Mul ple Projects targeted to Transform Business, ↓ Costs, ↑ Quality, Add New Business 1 Comprehensive Business Transformation Project 6 Innovation Projects Plants Infra Modernization‐Capacity Expansion 2 7 Digitalization Projects Projects 3 COGS Reduction Projects 8 M&A Proje
Slide 11: Building Competitiveness
Building Competitiveness : 3 3‐4x SOV; Product Re‐engineering; Profitable New Therapies entry from Day 1; Smart LCM; C3MP SoV with ~ 90000 docs up Manifold RPG Serv: ↑ Customer Coverage, ↑ SoV, ↑Engagement Smart Life cycle Management New New New New New Dosage New Brands Patient Customer/ Combinatio
Slide 12: Energizing Happy Teams: Happiness Framework
Energizing Happy Teams: Happiness Framework 4 People Initiatives for building a happy performance focussed culture I Love My Work I Feel Valued RPGLS Heroes I am Growing Outperformance recognition We Skill. You Grow. Competency building You Excel. We Applaud. continuum Motivation continuum Akanksha
Slide 13: Financial Performance
Financial Performance LZ An @> FPG Company = —————————— RPG LIFE SCIENCES
Slide 14: Q1 FY26 Performance
Q1 FY26 Performance (All figures in Rs. Crores) Revenue from Operations EBITDA & EBITDA Margin Figures in circle are Margins 2.1% ‐1.8% 165.4 168.9 41.4 40.7 25.1% 24.1% 17.5% Q1 FY25 Q1 FY26 Q1 FY25 Q1 FY26 PBT & PBT Margin PAT & PAT Margin ‐1.6% ‐1.8% 36.0 35.4 26.8 26.3 21.8% 21.0% 16.2% 15.6% Q1
Slide 15: Q1 FY26: Business Segment-wise Performance
Q1 FY26: Business Segment‐wise Performance Domestic Formulations contributed 69% to total sales of Q1 FY26 +9.5% • Continue to deliver market beating growth this quarter as well Domestic • New products contribution improving consistently on account of new launches in 105.5 115.5 Business Segments Fo
Slide 16: Key Financial Ratios Yearly Trends (ROCE, ROE, D/E)
Key Financial Ratios Yearly Trends (ROCE, ROE, D/E) ROCE% ROE% Debt/Equity Ratio 32.9% 31.6% 29.7% 28.5% 24.9% 23.4%24.3% 0.22 20.1% 22.0% 20.9% 18.5% 16.4% 9.7% 6.7% 0.06 0.01 0.00 0.00 0.00 0.00 FY19 FY20 FY21 FY22 FY23 FY24 FY25 * FY19 FY20 FY21 FY22 FY23 FY24 FY25 * FY19 FY20 FY21 FY22 FY23 FY24
Slide 17: RPG Life Sciences ICRA Rating Reaffirmation in FY25
RPG Life Sciences ICRA Rating Reaffirmation in FY25 A‐ (FY19) to A(FY21) to A+ (FY24) Improvements recorded in ICRA Rating Factors affecting rating affirmation • A robust capital structure and strong debt servicing indicators based on o Healthy cash flows • Long term rating o Company continues to re
Slide 18: Business Strategy
Business Strategy LZ An @> FPG Company = ——————————— RPG LIFE SCIENCES
Slide 19: Domestic Formulations (DF)
Domestic Formulations (DF) • Operating in Mass/Mass‐specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • Leading Textbook Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace • Leading player in Immunosuppressant category • Good Customer Coverage ‐ Cardiolo
Slide 20: International Formulations (IF) Business: Overview and Strategy
International Formulations (IF) Business: Overview and Strategy • Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets ‐ Canada, UK, Germany, France, Australia, South East Asia, Africa • Long lasting, impeccable supply track record and busine
Slide 21: APIs Business: Business Strategy and Way Forward
APIs Business: Business Strategy and Way Forward • High value, low volume, niche APIs • Footprints across geographies ‐ LATAM, Germany, China, • Mature stable molecules South Korea, Iran, Bangladesh, Egypt, India, etc. • Provides backward integration to • Strong customer focus – long‐lasting relatio
Slide 22: Infrastructure Capabilities & ESG Initiatives
Infrastructure Capabilities & ESG Initiatives 21
Slide 23: Manufacturing Facilities
Manufacturing Facilities Formulations Unit 1, Ankleshwar • F1 unit caters to the domestic and emerging markets • Multipurpose plant with dedicated product lines for oral dosage forms including tablets, liquids and powder • WHO, Kenya, Nigeria approved • Modernization cum Capacity Expansion underway
Slide 24: Digital Initiatives: Manufacturing and Quality
Digital Initiatives: Manufacturing and Quality Digital Retina Intelligent Chilling IOT based AHU Power Management Scanner Plant Manager monitoring system System • Biometric Access with IRIS/ Retina • Implementation • Operates Pumps • Safe, reliable, Scanner enables of Utility Asset & Chillers effici
Slide 25: ESG FY25 update
ESG FY25 update Initiatives FY25 • Carbon emission reduction ↓ FY24 : 26.8% ; FY25: 41.2 % Environmental • Energy Efficiency: Pumps; Chillers/Brine Plant; Leakages ↑ FY24: 26% ; FY25 : 41.0 % rectification • Water Management: Recycling of STP water; Rainwater ↓ FY 24: 6% ; FY25 : 7.0 % harvesting ↓
Slide 26: Journey Ahead
Journey Ahead LZ An @> FPG Company = ——————————— RPG LIFE SCIENCES
Slide 27: RPGLS Journey Ahead: strategic pillars of action
RPGLS Journey Ahead: 7 strategic pillars of action 1 Portfolio development • Project underway to grow our immunosuppressant portfolio to 200+ crores and mega‐brands building • Focused initiatives to grow Naprosyn to a 100+ crores brand; building our MABs portfolio 2 • Focus on new geographies, new l
Slide 28: RPG Life Sciences
000006 000 LZ An FPG Company RPG LIFE SCIENCES